Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06494397 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
A Phase 1 study, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT06494397 is a Phase 1 study that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT06494397, a Phase 1 study, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Study to compare the pharmacokinetics and pharmacodynamics of VHX-896 and iloperidone and evaluate the safety and tolerability of VHX-896 and iloperidone in patients with schizophrenia or bipolar I disorder under steady state conditions.
Interventions
- DRUG VHX-896 and iloperidone
- DRUG Iloperidone and VHX-896
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-07-11 |
| Est. Completion | 2024-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06494397
The ClinicalTrials.gov registry entry for NCT06494397 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VHX-896 and iloperidone is the first listed.
NCT06494397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06494397 about?
NCT06494397 is a clinical study titled "Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions". Study to compare the pharmacokinetics and pharmacodynamics of VHX-896 and iloperidone and evaluate the safety and tolerability of VHX-896 and iloperidone in patients with schizophrenia or bipolar I disorder under steady state conditions.
What is the current status of trial NCT06494397?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2024-07-11. Estimated completion is 2024-10-24.
What interventions are being tested in trial NCT06494397?
The interventions under investigation include: VHX-896 and iloperidone (DRUG), Iloperidone and VHX-896 (DRUG).
Who is sponsoring clinical trial NCT06494397?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.